Article
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan.
ESMO open - 1 Feb 2023
Su Y-Y, Chiang N-J, Chang J S, Wang Y-W, Shen B-N, Li Y-J, Hwang D-Y, Shan Y-S, Chen L-T
Abstract excerpt
BACKGROUND: Initial dose adjustment is recommended for patients with known UGT1A1∗28 homozygosity for both conventional irinotecan and liposomal irinotecan (nal-IRI). A recent population pharmacokinetic (PK) study showed that Asian patients had a lower prevalence of UGT1A1∗28 homozygosity but a significantly higher maximum blood concentration of SN-38 (SN-38 Cmax) and a higher incidence of grade ≥3 neutropenia...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.